Medtronic Issues Class I Recall for StealthStation S8 Software Due to Critical Display Errors
Medtronic
Chronic Disease Medical Device and Therapy Developer
Source: Siyu MedTech; Editor: Sophia
Reprint Requirements: Please indicate the source of the article at the beginning of the text, and you can reprint it directly.
Audience Registration Open! The First Global Medical Technology Conference
Following customer complaints about software errors causing missing and replacement issues with numbers or letters in displayed text, Medtronic is recalling multiple versions of the StealthStation S8 application (including versions 1.2.0, 1.1.0, 1.0.3, 1.0.2, and 1.0.1).
# The Product Was Subject to a Class I Recall Last Year
On December 19, 2023, the U.S. FDA classified Medtronic's voluntary recall initiated on September 27, 2023, as a Class I recall.
However, the FDA also pointed out that this recall only involves a software update for the navigation robot, not a product replacement. The affected software versions are StealthStation S8 2.0 and 2.0.1, as well as 2,109 navigation systems sold in the U.S. from January 7, 2022, to October 2, 2023.
The reason for the recall is a software malfunction, which may lead toThe surgical planning data experienced a positional shift after the initial test was modified, appearing in an unintended location during the surgery.
Using the affected product may lead to serious consequences, including death.
# Stealth Station S8
Revolutionizing Visualization Technology: Augmented Reality Platform Enhances Cranial Surgery
Key features of the system include：
Preset trajectory projection helps doctors plan the movement path of tools before surgery.
Adjust the transparency of surgical tools to optimize the visualization of the surgical area.
Pre-select implants and quickly access surgical tools during the operation.
With O-armO2Imaging system integration reduces reliance on intraoperative fluoroscopy and lowers radiation exposure risks for doctors and staff.
In 2021, Medtronic announced its collaboration withMarket Leader in VR/AR Healthcare ServicesSurgical Theatre Cooperation,Provide an augmented reality platform for skull surgery.
Treating brain tumors, aneurysms, and neurological disorders ranks among the highest-risk and most complex surgical procedures. Real-time access to the most detailed patient-specific information, such as the spatial relationships between vascular structures, arteries, and white matter locations, is crucial.
Medtronic will integrate the Stealth Station S8 surgical navigation system withSurgical TheatreTheSyncAR TechnologyConnected, will360° Rendering Coverage ARBring into cranial surgery to enhance the visibility of neurosurgeons during the surgical process.
SyncAR technology aims to allow surgeons, before entering the operating room, to visualize brain structures through rehearsal simulation technology, test virtual surgical tools, and plan surgeries.
Medtronic is a global leading medical technology company, founded in 1949, with its headquarters located in Minnesota, USA. The main product lines of Medtronic areCardiovascular, Surgical and Critical Care, Neuroscience, and Diabetes: covering arrhythmia, heart failure, cardiac intervention, heart valve replacement, diabetes, gastrointestinal diseases, urological diseases, spinal diseases, and neurological diseases.And product and service systems in the fields of otorhinolaryngology, etc.
Editor-in-Chief | Zhao Qing Reviewed by | Yi He
